MedTrace Logo

Phase II Trial of Lung Chemoemobolization

NCT05672108 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-05

No results posted yet for this study

Summary

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.

Conditions

  • Lung Non-Small Cell Carcinoma
  • Mediastinal Neoplasm
  • Pleural Neoplasm
  • Lung Metastases From Any Primary
  • Endobronchial Metastases
  • Colon Cancer
  • Sarcoma

Interventions

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Ethiodized Oil

Given IA

DRUG

Mitomycin

Given IA

PROCEDURE

Transarterial Chemoembolization

Undergo TACE

DEVICE

Tris-acryl Gelatin Microspheres

Given IA

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Franz E Boas, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-12
Primary Completion
2027-10-28
Completion
2027-10-28
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672108 on ClinicalTrials.gov